Posted on May 19th, 2015 by
Class: Biological Therapy
Generic Name: Blinatumomab
Trade Name: Blincyto®
For which conditions is this drug approved? Blincyto is approved for treatment of a certain type of acute lymphoblastic leukemia (ALL): Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute ALL.
What is the mechanism of action? Blincyto is a type of drug known as a monoclonal antibody. Monoclonal antibodies target and attach to cancer cells, which tells the immune system to destroy the cancer. Specifically, Blincyto targets a protein called CD19 that’s found on the surface of B-cell leukemia cells. Another protein, CD3, that’s found on the surface of T-cell lymphocytes (part of the immune system), then connects with CD19 to destroy the cancer cells.
How is Blincyto typically given (administered)? Blincyto is given by intravenous (IV) infusion into your vein using an infusion pump. One treatment cycle includes a continuous IV infusion for four weeks, followed by a two-week break during which you will not be given Blincyto. After the two-week break, your healthcare provider will decide if you will be given Blincyto for additional treatment cycles.
How are patients typically monitored? While you’re receiving Blincyto, your doctor will monitor you for signs or symptoms of infection.
What are the common (occur in 30% or more of patients) side effects of treatment with Blincyto?
What are the less common (occur in 10% to 29% of patients) side effects of treatment with Blincyto?
This is not a complete list of side effects. Some patients may experience other side effects that are not listed here. Patients may wish to discuss with their physician the other less common side effects of this drug, some of which may be serious.
Some side effects may require medical attention. Other side effects do not require medical attention and may go away during treatment. Patients should check with their physician about any side effects that continue or are bothersome.
What can patients do to help alleviate or prevent discomfort and side effects?
Are there any special precautions patients should be aware of before starting treatment?
When should patients notify their physician?
What is a package insert?
A package insert is required by the FDA and contains a summary of the essential scientific information needed for the safe and effective use of the drug for healthcare providers and consumers. A package insert typically includes information regarding specific indications, administration schedules, dosing, side effects, contraindications, results from some clinical trials, chemical structure, pharmacokinetics and metabolism of the specific drug. By carefully reviewing the package insert, you will get the most complete and current information about how to safely use this drug. If you do not have the package insert for the drug you are using, your pharmacist or physician may be able to provide you with a copy.
You must be logged-in to the site to post a comment.